<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>VDAC2 protein inhibition &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/vdac2-protein-inhibition/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 12:50:13 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>VDAC2 protein inhibition &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Eliminating a Protein ‘Signal Jammer’ Enhances Immunotherapy Effectiveness</title>
		<link>https://bioengineer.org/eliminating-a-protein-signal-jammer-enhances-immunotherapy-effectiveness/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 19 Mar 2025 20:37:02 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer immunotherapy breakthroughs]]></category>
		<category><![CDATA[CRISPR-Cas9 in cancer research]]></category>
		<category><![CDATA[Mitochondrial DNA in immune response]]></category>
		<category><![CDATA[Tumor immune evasion mechanisms]]></category>
		<category><![CDATA[VDAC2 protein inhibition]]></category>
		<guid isPermaLink="false">https://bioengineer.org/eliminating-a-protein-signal-jammer-enhances-immunotherapy-effectiveness/</guid>

					<description><![CDATA[In a groundbreaking study published in Nature, researchers from St. Jude Children’s Research Hospital have unveiled new insights into tumor immunology that could revolutionize cancer treatment, especially for pediatric solid tumors that exhibit resistance to existing therapies. The research focuses on a specific protein known as voltage-dependent anion channel 2 (VDAC2), which plays a critical [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">238792</post-id>	</item>
	</channel>
</rss>
